X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The last patient was treated with AsiDNA™ in combination with carboplatin and paclitaxel in this Phase 1b study in patients with advanced solid tumors.
Lead Product(s): AsiDNA,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: AsiDNA
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
This patent will provide a term of protection until 2036. It completes the already robust set of patent families protecting AsiDNA™ and its related compounds, alone or in combination.
Lead Product(s): AsiDNA,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: AsiDNA
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 22, 2020
Details:
Revocan phase 1b/2 study is designed to evaluate the effect of AsiDNA™, Onxeo’s first-in-class DDR inhibitor, on the acquired resistance to PARP inhibitor (PARPi) niraparib for second line maintenance treatment of relapsed ovarian cancer.
Lead Product(s): AsiDNA,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: AsiDNA
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose used today in the ongoing DRIIV-1b and REVOCAN studies of AsiDNA™ in combination with chemotherapy and PARP inhibitors .
Lead Product(s): AsiDNA,Carboplatin,Paclitaxel
Therapeutic Area: Oncology Product Name: AsiDNA
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer.
Lead Product(s): AsiDNA,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2020
Details:
Preclinical data supports the differentiated ability of AsiDNA™, its first-in-class DNA Damage Response (DDR) inhibitor, to reverse resistance to PARP inhibitors (PARPi) by preventing death-tolerant cells (DTC) regrowth.
Lead Product(s): AsiDNA,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2020
Details:
The new Agreement grants Acrotech a royalty-free license to belinostat in all other territories including the United States, Canada, Mexico, and India.
Lead Product(s): Belinostat
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Acrotech Biopharma
Deal Size: $6.6 million Upfront Cash: $6.6 million
Deal Type: Agreement April 06, 2020
Details:
The data will showcase the high affinity with PARP that leads to DDR inhibition, metabolic exhaustion and activation of the innate immune response, specifically in tumoral cells.
Lead Product(s): OX401
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
Details:
The REVOCAN ph 1b/2 study, will evaluate the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in 2nd line maintenance treatment of relapsed ovarian cancer.
Lead Product(s): AsiDNA,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020
Details:
The collaboration aims to conduct the REVOCAN phase 1b/2 study designed to evaluate the effect of AsiDNA, Onxeo’s first-in-class DDR inhibitor, on the acquired resistance to PARPi niraparib in its approved indication for the treatment of relapsed ovarian cancer.
Lead Product(s): AsiDNA,Niraparib Tosylate
Therapeutic Area: Oncology Product Name: AsiDNA
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Gustave Roussy
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
